Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.
Shu NingJinge ZhaoAlan P LombardLeandro S D'AbronzoAmy R LeslieMasuda SharifiWei LouChengfei LiuJoy C YangChristopher P EvansEva CoreyHong-Wu ChenAi-Ming YuParamita M GhoshAllen C GaoPublished in: Communications medicine (2022)
The 95 neural lineage gene signatures capture an early molecular shift toward neuroendocrine differentiation, which could stratify advanced prostate cancer patients to optimize clinical treatment and serve as a source of potential therapeutic targets in advanced prostate cancer.